NCT03816319 2026-05-18TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsNational Cancer Institute (NCI)Phase 1 Suspended42 enrolled